Jialiang Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jialiang Liu has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Ang Gao
O’Donnell School of Public Health, University of Texas Southwestern Medical Center, Dallas, USA
20 shared publications - Arjun Gupta
City of Hope Cancer Center, Phoenix, AZ
20 shared publications - David E. Gerber
Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center , Dallas, TX
20 shared publications - David Ross Camidge
University of Colorado Cancer Center, Aurora, CO 80045, USA
20 shared publications - Farjana Fattah
Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas
20 shared publications - Hong Mu-Mosley
Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas
20 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by Springer Nature in Journal of Experimental Criminology
- p. 1-9
Identifying language associated with probation absconding using natural language processing: a proof-of-concept study
- 14 October 2026
- Published by Springer Nature in Journal of Experimental Criminology
- p. 1-9
Open AccessIdentifying language associated with probation absconding using natural language processing: a proof-of-concept study
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Figure 4. Cytokine changes (post-selinexor, pre-docetaxel) significantly associated with clinical outcomes.
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Figure 4. Cytokine changes (post-selinexor, pre-docetaxel) significantly associated with clinical outcomes.
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Figure 1. Next generation sequencing results (n=16 cases).
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Figure 1. Next generation sequencing results (n=16 cases).
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Figure 3. Baseline cytokines significantly associated with clinical outcomes.
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Figure 3. Baseline cytokines significantly associated with clinical outcomes.
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Figure 2. Transcriptional signatures identified through RNA sequencing.
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Figure 2. Transcriptional signatures identified through RNA sequencing.
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Figure 2. Transcriptional signatures identified through RNA sequencing.
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Figure 2. Transcriptional signatures identified through RNA sequencing.
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Figure 5. Sample radiographic responses (n=3, all TP53 wild type).
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Figure 5. Sample radiographic responses (n=3, all TP53 wild type).
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Table 1. Representativeness of study participants.
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Table 1. Representativeness of study participants.
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Data from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Purpose:Patients with Kirsten rat sarcoma viral oncogene (KRAS)–mutant non–small cell lung cancer (NSCLC) have limited therapeutic options. Based on the activity of nuclear export inhibition in preclinical models, we evaluated this strategy in previously treated, advanced KRAS-mutant NSCLC.Patients and Methods:The primary outcomes of this multicenter phase I/II dose-escalation trial of selinexor plus docetaxel were safety and tolerability. Selinexor was started 1 week before docetaxel to permit monotherapy pharmacodynamic assessment.Results:Among 40 enrolled patients, the median age was 66 years, 55% were female, and 85% were White. The MTD was selinexor 60 mg orally weekly plus docetaxel 75 mg/m2 every 3 weeks. The most common adverse events were nausea (73%, 8% grade ≥3), fatigue (70%, 5% grade ≥3), neutropenia (65%, 60% grade ≥3), and diarrhea (58%, 10% grade ≥3). Of 32 efficacy-evaluable patients, 7 (22%) had partial responses and 18 (56%) had stable disease. Outcomes were not associated with KRAS mutation type but were significantly better in cases with wild-type TP53 (42%), including response and disease control rates (27% and 80% vs. 9% and 27%, respectively; P = 0.03) and progression-free survival (median 7.4 vs. 1.8 months; HR, 0.2; 95% confidence interval, 0.07–0.67; P = 0.003). After selinexor initiation and prior to docetaxel administration, serum lactate dehydrogenase levels increased an average of 51 U/L in TP53-altered cases and decreased an average of 48 U/L in TP53 wild-type cases (P = 0.06).Conclusions:Selinexor plus docetaxel was relatively well tolerated in patients with advanced KRAS-mutant NSCLC. The regimen has promising efficacy in TP53 wild-type cases, in which selinexor monotherapy may also have activity.
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Purpose:Patients with Kirsten rat sarcoma viral oncogene (KRAS)–mutant non–small cell lung cancer (NSCLC) have limited therapeutic options. Based on the activity of nuclear export inhibition in preclinical models, we evaluated this strategy in previously treated, advanced KRAS-mutant NSCLC.Patients and Methods:The primary outcomes of this multicenter phase I/II dose-escalation trial of selinexor plus docetaxel were safety and tolerability. Selinexor was started 1 week before docetaxel to permit monotherapy pharmacodynamic assessment.Results:Among 40 enrolled patients, the median age was 66 years, 55% were female, and 85% were White. The MTD was selinexor 60 mg orally weekly plus docetaxel 75 mg/m2 every 3 weeks. The most common adverse events were nausea (73%, 8% grade ≥3), fatigue (70%, 5% grade ≥3), neutropenia (65%, 60% grade ≥3), and diarrhea (58%, 10% grade ≥3). Of 32 efficacy-evaluable patients, 7 (22%) had partial responses and 18 (56%) had stable disease. Outcomes were not associated with KRAS mutation type but were significantly better in cases with wild-type TP53 (42%), including response and disease control rates (27% and 80% vs. 9% and 27%, respectively; P = 0.03) and progression-free survival (median 7.4 vs. 1.8 months; HR, 0.2; 95% confidence interval, 0.07–0.67; P = 0.003). After selinexor initiation and prior to docetaxel administration, serum lactate dehydrogenase levels increased an average of 51 U/L in TP53-altered cases and decreased an average of 48 U/L in TP53 wild-type cases (P = 0.06).Conclusions:Selinexor plus docetaxel was relatively well tolerated in patients with advanced KRAS-mutant NSCLC. The regimen has promising efficacy in TP53 wild-type cases, in which selinexor monotherapy may also have activity.
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Figure 5. Sample radiographic responses (n=3, all TP53 wild type).
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non–Small Cell Lung Cancer
Supplemental Figure 5. Sample radiographic responses (n=3, all TP53 wild type).